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a b s t r a c t
Background: Gaucher Disease type 1 (GD1) often manifests in childhood. Early treatment with enzyme
replacement therapy (ERT) may prevent disease complications. We report the assessment of velaglucerase alfa
ERT in pediatric GD1 patients who participated in a long-term extension study (HGT-GCB-044, ClinicalTrials.gov
Identiﬁer NCT00635427).
Methods: Safety and efﬁcacy were evaluated in pediatric patients receiving velaglucerase alfa 30–60 U/kg by
intravenous infusion every other week. In addition to key hematological and visceral efﬁcacy assessments,
exploratory assessments conducted speciﬁcally in pediatric patients included evaluation of height, bone age,
bone marrow burden, and Tanner stage of puberty.
Results: The study included 24 pediatric patients. Fifteen patients were naïve to ERT on entry into the preceding
trials TKT032 (12-month trial) or HGT-GCB-039 (9-month trial): in the preceding trials, ten of these 15 patients
received velaglucerase alfa and ﬁve patients received imiglucerase ERT. Nine patients in the study were
previously treated with imiglucerase for N 30 months and were switched to velaglucerase alfa in the preceding
trial TKT034 (12-month trial). Cumulative ERT exposure in the clinical studies ranged from 2.0 to 5.8 years.
Three serious adverse events, including a fatal convulsion, were reported; none were deemed related to
velaglucerase alfa. One patient tested positive for anti-velaglucerase alfa antibodies. An efﬁcacy assessment at
24 months showed that velaglucerase alfa had positive effects on primary hematological and visceral parameters
in treatment-naïve patients, which were maintained with longer-term treatment. Disease parameters were
stable in patients switched from long-term imiglucerase ERT. Exploratory results may suggest beneﬁts of early
treatment to enable normal growth in pediatric patients.
Conclusion: The safety proﬁle and clinical response seen in pediatric patients are consistent with results reported
in adults.
© 2016 Shire Development LLC. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Abbreviations: AE, adverse event; BMB, bone marrow burden; BW, body weight; CCL18, chemokine (C–C motif) ligand 18; EOW, every other week; ERT, enzyme replacement therapy; GD,
Gaucher disease; ICH, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; IgG, immunoglobulin G; IRAE, infusionrelated adverse event; LS, lumbar spine; MN, multiples of normal; MRI, magnetic resonance imaging; SAE, serious adverse event; TEAE, treatment-emergent adverse event.
⁎ Corresponding author.
E-mail address: ldsmith@cmh.edu (L. Smith).
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1096-7192/© 2016 Shire Development LLC. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Gaucher disease (GD) is a lysosomal storage disorder caused by
a deﬁciency of β-glucocerebrosidase that leads to accumulation of
glucocerebroside in the cells of the monocyte–macrophage system.
Many patients with GD type 1 (GD1) have signs or symptoms during
childhood, which include anemia, thrombocytopenia, hepatosplenomegaly, bone disease, pubertal delay and growth retardation [1–3].
GD has a broad spectrum of clinical presentation for which three
subtypes are described: GD1 is characterized by the lack of neurologic
involvement, whereas GD2 and GD3 present with acute and chronic
neurologic involvement, respectively. As chronic neurologic symptoms
may not develop until late childhood or adolescence, children presenting with GD should be treated with a high index of suspicion for GD3,
particularly in cases of non-N370S genotypes (as carrying at least one
N370S allele is negatively associated with neuronopathic disease) or homozygosity for L444P (as this genotype is commonly seen in GD3) [4,5].
Early intervention with glucocerebrosidase enzyme replacement
therapy (ERT) during childhood can avoid complications from disease
symptoms, and may prevent progression of irreversible skeletal
manifestations [6]. ERT does not slow progression of the neurologic
symptoms of GD3, but can alleviate systemic symptoms, greatly
improving quality of life [7].
Velaglucerase alfa (VPRIV®) and imiglucerase (Cerezyme®) are
indicated as ERTs for the treatment of GD1. Analyses of registry data
on pediatric patients treated with imiglucerase (and/or alglucerase)
have shown that normalization or near-normalization of clinical parameters can be achieved with long-term therapy [8,9]. There are currently
limited data on the effects of velaglucerase alfa in children, and clinical
trial evidence on pediatric-speciﬁc parameters such as growth and
development, is lacking.
Velaglucerase alfa was assessed in adult and pediatric patients
in three clinical trials that were followed by a single extension study:
TKT032 [10] and HGT-GCB-039 [11] were Phase III parallel-group
clinical trials conducted in treatment-naïve patients with GD1. TKT032
was an assessment of two doses of velaglucerase alfa, whereas HGTGCB-039 was a non-inferiority study comparing velaglucerase alfa
with imiglucerase. TKT034 [12] was a Phase II/III trial assessing
velaglucerase alfa in GD1 patients previously treated with imiglucerase.
HGT-GCB-044 was an extension study of the preceding trials
TKT032, HGT-GCB-039 and TKT034; the primary objective was to
evaluate the long-term safety of velaglucerase alfa ERT. We report the
safety and efﬁcacy of velaglucerase alfa in the pediatric population of
the extension study (25% of the study population), including assessments conducted speciﬁcally in children to evaluate bone disease.
2. Methods
2.1. Patients
HGT-GCB-044 was an open-label, multicenter extension study
conducted from March 2008 to December 2012. Patients who completed one of three preceding trials, TKT032 (two-dose assessment;
51 weeks), HGT-GCB-039 (non-inferiority trial; 39 weeks) or TKT034
(switch trial; 51 weeks), were eligible to enroll (Fig. 1). A documented
diagnosis of GD was required for inclusion in the preceding trials as
determined by either deﬁcient glucocerebrosidase activity, or by
genotype analysis. Patients were examined by their treating physician
and were clinically judged to have GD1 based on the absence of neurologic signs or symptoms. Patients with GD2 or GD3, or who were suspected
of having GD3, were excluded; patients who had signiﬁcant comorbidities
or were unable to comply with the protocol were also excluded. GBA
genotyping of all patients was conducted at a central laboratory following
enrollment (Emory Genetics Laboratory, Decatur, GA) [10,11].
The extension study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Pediatric patients
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provided written informed consent (and assent where applicable) to
participate via a parent or legal guardian.
Patients who completed the TKT032 two-dose assessment and HGTGCB-039 non-inferiority trial were assigned to receive velaglucerase
alfa at 60 U/kg every other week (EOW). Patients who completed the
TKT034 switch trial were assigned to receive velaglucerase alfa at the
same dose they received during TKT034 (range 15–60 U/kg).
Velaglucerase alfa was administered by intravenous infusion over
60 min. Patients could remain in the extension study until commercial
velaglucerase alfa became available to them or the study was discontinued, or until early discontinuation from the study.
2.2. Safety assessments
Evaluation of the long-term safety of velaglucerase alfa was the
primary objective of the extension study. Safety was evaluated by
continuous monitoring for adverse events (AEs) and assessment of
vital signs at each infusion visit. Treatment emergent AEs (TEAEs)
were those that occurred within the time of or after the ﬁrst infusion
in the extension study until 30 days after the last infusion in the
study. Infusion-related AEs (IRAEs) were those that began during or
within 12 h of an infusion start time, and deemed possibly or probably
related to velaglucerase alfa.
Approximately every 3 months, patients underwent physical
examination and safety-related laboratory testing, and had blood samples screened for anti-velaglucerase alfa antibodies. Antibody-positive
samples were isotyped and assessed for enzyme neutralizing activity.
2.3. Efﬁcacy assessments
The secondary objectives of the extension study were to evaluate
the effects of velaglucerase alfa on hemoglobin concentration,
platelet count, and spleen and liver volumes. The exploratory objectives were to assess the effects of velaglucerase alfa on the GD plasma biomarkers chitotriosidase and chemokine (C–C motif) ligand
18 (CCL18); bone mineral density and serum bone biomarkers in
adults (not described here); and growth velocity (height), bone
age, bone marrow burden (BMB) and Tanner stage in pediatric patients. Efﬁcacy results were determined from the start of the preceding trials.
Blood samples were collected every 3 months and evaluated for
hemoglobin concentration, platelet count, chitotriosidase activity and
CCL18 level. Spleen and liver volumes were measured annually using
quantitative abdominal magnetic resonance imaging (MRI).
Height measurements were recorded every 3 months. For comparison across ages and sexes, measurements were converted to Z-scores
using World Health Organization 2007 growth reference data. Growth
velocity was calculated as change in height from baseline over regular
intervals (Supplementary material).
Bone age was evaluated annually by radiographs of the left hand
and wrist. Radiographs were interpreted by one radiologist with no
knowledge of the patient's chronological age. Bone ages were converted to Z-scores based on standards recommended by Greulich
and Pyle [13].
BMB was evaluated annually by MRI of the lumbar spine (LS) and
femur (Supplementary material).
Patients who turned 18 years of age during the study continued to
have their height, bone age and BMB assessed as described above.
Tanner Stage of Puberty [14] was assessed annually. Assessments
ceased once a patient reached the ﬁnal stage of the Tanner scale
(stage 5), or turned 18 years of age.
2.4. Statistical analysis
Pediatric patients were those 2 to b18 years of age at entry into the
preceding trials. The safety population was deﬁned as all patients who
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Fig. 1. Study design and grouping of pediatric patients in HGT-GCB-044. For all analyses, patients were grouped into three populations according to their participation in the preceding
trials. The Overall Vela population comprised ten patients who received at least one dose of velaglucerase alfa in the TKT032 two-dose assessment (7 patients) or HGT-GCB-039 noninferiority trial (3 patients). Two patients in this group were the carriers excluded from the efﬁcacy analysis. The Imi-Vela population comprised ﬁve patients who received imiglucerase
in the HGT-GCB-039 non-inferiority trial and transitioned to velaglucerase alfa in the extension study. The Switch population comprised nine patients previously treated with imiglucerase
who switched to velaglucerase alfa in the TKT034 switch trial and continued to receive velaglucerase alfa in the extension study. 1Patients who completed TKT034 received velaglucerase
alfa at the same dose they received during TKT034, which could range from 15 to 60 U/kg.

received at least one dose of velaglucerase alfa during the extension
study. Safety data are presented from the start of the extension study.
No formal statistical tests were performed on safety parameters.
Two pediatric patients from TKT032 (two-dose assessment) were
diagnosed with GD1 based on a false-positive dried-blood-spot test
showing glucocerebrosidase deﬁciency. Later testing determined these
patients to be genetic carriers and they were immediately withdrawn
from the study [10]. These carriers were excluded from the efﬁcacy
analysis population deﬁned as all patients with GD1 enrolled in the
extension study. However, by the conservative safety principle (any
subject who received at least one dose of the study drug) and per the
ICH E9 guidelines ‘Statistical Principles for Clinical Trials’, they were
included in the safety population.
Changes and mean changes from baseline in efﬁcacy parameters were
calculated. Baseline was deﬁned as data obtained prior to receiving the
ﬁrst dose of study drug at the start of TKT032, HGT-GCB-039 or TKT034.
An efﬁcacy analysis was conducted at 24 months, in addition to a longitudinal analysis calculating changes from baseline at each study time point.
Three analysis populations were deﬁned based on participation in
the preceding trials: Overall Vela, Imi-Vela and Switch.
3. Results
3.1. Patients
Twenty-four pediatric patients enrolled in the extension study
(95 patients enrolled in total). The Overall Vela population comprised
10 patients who received velaglucerase alfa in TKT032 (two-dose
assessment) or HGT-GCB-039 (non-inferiority trial). Two individuals,
who were carriers in TKT032, were excluded from the ﬁnal efﬁcacy
analysis population of eight patients. The Imi-Vela population comprised ﬁve patients who received imiglucerase in the HGT-GCB-039
non-inferiority trial. The Switch population comprised nine patients
previously treated with imiglucerase who switched to velaglucerase
alfa in the TKT034 switch trial (Fig. 1).
Pediatric patients ranged in age from 3 to 16 years at baseline
(Table 1). Imi-Vela patients were younger than those in the other two
groups. N370S was the most prevalent GBA mutation present in the
Switch population. Mutations that have been associated with more severe disease or neuronopathic GD were present in the Overall Vela

and Imi-Vela populations, including L444P/L444P, F213I/F213I and
D409H/L444P; all patients were clinically judged to have GD1 at study
enrollment. Treatment-naïve patients (Overall Vela and Imi-Vela)
showed more severe disease at baseline than patients previously
treated with imiglucerase (Switch) (Table 2).
All patients completed 24 months of treatment from baseline; time
in the study after 24 months was variable as patients transitioned
to commercial velaglucerase alfa (ﬁrst available in February 2010).
The median duration of exposure to study drug from baseline to last
infusion was 53 (range 47–69) months for the Overall Vela population,
52 (33–54) months for the Imi-Vela population (combined exposure to
imiglucerase and velaglucerase alfa) and 33 (24–63) months for the
Switch population. The shorter duration of exposure in the Switch
group is due to six of nine patients being in the United States and
transitioning sooner to commercial therapy, whereas Overall Vela and
Imi-Vela patients were in countries where velaglucerase alfa received
market approval later.
Overall Vela patients received velaglucerase alfa at 45 U/kg (two
patients) or 60 U/kg (six patients) during the TKT032 two-dose assessment or HGT-GCB-039 non-inferiority trial whereas Imi-Vela patients
received imiglucerase at 60 U/kg during HGT-GCB-039 (Fig. 1). All
Overall Vela and Imi-Vela patients received velaglucerase alfa at 60 U/kg
during the extension study.
Switch patients received velaglucerase alfa at 30 U/kg (two patients),
45 U/kg (three patients) and 60 U/kg (four patients); these doses were
the same as the doses of imiglucerase received prior to switching to
velaglucerase alfa in TKT034.
3.2. Safety in the extension study
All 24 patients experienced at least one AE during the extension
study (Supplemental Table 1). The most common TEAEs were upper
respiratory tract infection, nasopharyngitis and headache. Seven
patients experienced at least one study drug-related AE. Three patients
experienced at least one IRAE. One patient experienced three serious
AEs (SAEs) of respiratory tract infection, bronchopneumonia and a
convulsion, all deemed unrelated to velaglucerase alfa. The convulsion
was fatal; it was considered by the investigator to be related to GD
progression. The patient was a male with GBA genotype F213I/F213I,
aged 3 years at baseline and 6 years at the time of the convulsion. He

L. Smith et al. / Molecular Genetics and Metabolism 117 (2016) 164–171

167

Table 1
Patient ages at baseline, start of extension study and last study visit.
Patient

Sex, GBA genotype

Age at baseline (years)

Age at start of extension study (years)

Age at ﬁnal study visit (years)

Overall Vela
1
2
3
4
5
6
7
8

F, D409H/L444P
M, D409H/L444P
M, N370S/RecNciIa
M, N370S/RecNciI
F, D409H/F411I
M, N370S/N370S
M, L444P/L444Pb
M, L444P/L444Pb

7
6
9
16
6
14
14
7

8
7
10
17
7
14
15
8

11
10
15
22
11
18
18
11

Imi-Vela
9
10
11
12
13

F, N370S/L444P
M, L444P/L444Pb
M, L444P/L444Pb
M, F213I/F213I
M, F213I/F213I

7
4
3
3
3

8
5
4
4
4

10
8
8
8
6

Switch
14
15
16
17
18
19
20
21
22

F, G46E/L444P
F, N370S/L324P
F, N370S/L444R
F, N370S/84GG
M, N370S/L444P
F, N370S/L444P
F, N370S/RecNciI
F, N370S/RecNciI
M, N370S/RecNciI

9
14
14
12
13
13
10
16
14

10
15
15
13
14
14
12
17
15

14
17
20
15
16
16
12
18
16

Baseline is the start of preceding trials TKT032, HGT-GCB-039 or TKT034.
a
The RecNciI allele results from recombination between GBA and its downstream pseudogene, and carries the pseudogene-derived L444P and A456P amino acid substitutions.
b
Although this genotype is commonly seen in GD3, a diagnosis of GD type cannot be made based on genotype alone and these patients were clinically judged by their treating physician
to have GD1 at study enrollment.

experienced a seizure 3 days after an imiglucerase infusion in the HGTGCB-039 non-inferiority trial, and a second seizure 10 days after a
velaglucerase alfa infusion in the extension study. Both seizures were
moderate, non-serious and deemed unrelated to the study drug. He also
experienced a non-serious event of gait disturbance during the extension
study unrelated to velaglucerase alfa. The patient received 24 months of

velaglucerase alfa treatment; his last dose was administered 12 days before the fatal convulsion. The patient was diagnosed with GD1 at entry
into HGT-GCB-039, though it is noted that the neurologic symptoms he
developed during study participation are suggestive of GD3.
Thirteen bone-related AEs were experienced by eight patients
during the extension study, including one event of bone pain, two of

Table 2
Baseline characteristics of the efﬁcacy analysis pediatric population.
Baseline factor

Males
n (%)
Age
Median (range), years
GBA genotype
N370S/N370S
N370S/84GG
N370S/L444P
L444P/L444Pa
N370S/RecNciI
N370S/L324P
N370S/L444R
D409H/L444P
G46E/L444P
D409H/F411I
F213I/F213I
Splenectomized
n
Efﬁcacy variables
Median (range)
Hemoglobin concentration, g/dL
Platelet count, ×109/L
Spleen volume, multiples of normal
Liver volume, multiples of normal
Chitotriosidase, nmol/mL/h
CCL18, ng/mL

Overall Vela

Imi-Vela

Switch

N=8

N=5

N=9

6 (75%)

4 (80%)

2 (22%)

8 (6–16)

3 (3–7)

13 (9–16)

1
0
0
2
2
0
0
2
0
1
0

0
0
1
2
0
0
0
0
0
0
2

0
1
2
0
3
1
1
0
1
0
0

1

1

0

10.75 (10.0, 12.4)
116 (44, 292)
14.3 (4.8, 35.0)
1.6 (1.1, 2.1)
38,718 (19,856, 63,182)
1713 (1094, 2793)

9.50 (8.1, 11.5)
73 (63, 188)
40.35 (6.5, 44.4)
2.2 (1.5, 2.8)
56,625 (27,438, 99,390)
1750 (960, 5902)

13.30 (11.5, 15.3)
169 (139, 277)
3.2 (1.7, 4.3)
0.8 (0.6, 1.0)
4169 (1465, 12,460)
211 (67, 935)

Baseline is the start of preceding trials TKT032, HGT-GCB-039 or TKT034.
a
Although this genotype is commonly seen in GD3, a diagnosis of GD type cannot be made based on genotype alone and these patients were clinically judged by their treating physician
to have GD1 at study enrollment.
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foot fracture (in the same patient), three of pain in an extremity, and
seven related to injury. All were mild or moderate in intensity and all
were deemed unrelated to velaglucerase alfa except for one incidence
of muscular pain in the calf at rest that was deemed possibly related.

No patients withdrew from the study due to an AE. The AE proﬁle
of pediatric patients in the extension study did not identify additional
safety concerns compared with the complete extension study population (Supplemental Table 2).

Fig. 2. Observed values of primary efﬁcacy parameters in individual patients over time. (A and B) In Overall Vela and Imi-Vela patients, increases in hemoglobin concentration and platelet
count, and decreases in spleen and liver volume were seen within 24 months, and changes were generally maintained for the duration of the study. (C) The efﬁcacy parameters of patients
previously treated with imiglucerase were stable following transition to velaglucerase alfa. Organ volumes were expressed normalized to body weight (% BW); one multiple of normal was
deﬁned as 0.2% BW for spleen volume and 2.5% BW for liver volume. Lines marked with circles (○) indicate splenectomized patients. MN: multiples of normal.

L. Smith et al. / Molecular Genetics and Metabolism 117 (2016) 164–171

There were no clinically signiﬁcant trends in vital signs or physical examination ﬁndings to suggest an increased safety risk with velaglucerase
alfa.
One 12-year-old Switch patient, positive for anti-imiglucerase IgG
antibodies with a high titer of 191,100 ng/mL at baseline [12], tested
positive for anti-velaglucerase alfa IgG antibodies at week 77 and
continued to test positive for the remainder of the study. The samples
from this patient that tested anti-velaglucerase alfa antibody positive
were further analyzed using an enzymatic activity neutralization assay
and were shown to have neutralizing antibody activity. No apparent
impact was noted on the efﬁcacy of velaglucerase alfa as assessed by
changes in hemoglobin concentration and platelet count. The patient
did not experience any drug-related AEs.

3.3. Efﬁcacy evaluations
The 0–24 month analysis in Overall Vela and Imi-Vela patients
showed favorable changes from baseline in all primary efﬁcacy parameters (Supplemental Table 3). Mean changes from 0 to 24 months
in Switch patients indicated that parameters were generally stable
(Supplemental Table 3). Longitudinal measurements over up to
5.8 years of treatment showed that positive changes in primary efﬁcacy
parameters in Overall Vela and Imi-Vela patients were maintained
(Fig. 2A and B). Primary efﬁcacy parameters in Switch patients continued to be stable for up to 5.3 years of treatment (Fig. 2C).
Chitotriosidase activity decreased in Overall Vela and Imi-Vela
patients, and also continued to decrease in Switch patients following
transition to velaglucerase alfa (Supplemental Table 3). These reduced
activity levels were maintained in the extension study (data not
shown). Similarly, decreases in CCL18 level were seen in all three
populations (Supplemental Table 3).
From 0 to 24 months, mean height Z-scores increased in the Overall
Vela and Imi-Vela populations and were stable in the Switch population
(Supplemental Table 3). Beyond 24 months, height Z-scores continued
to increase in the Overall Vela population and were maintained in the
Imi-Vela and Switch populations, though the number of patients with
evaluable assessments was small (Table 3).
At 24 months, the mean change from baseline in bone age Z-scores
was + 1.3, − 0.1 and + 0.7 for the Overall Vela, Imi-Vela and Switch
populations, respectively (Supplemental Table 3). Bone age Z-scores
increased beyond 24 months in the Overall Vela population and were
stable in the Switch population (Table 3). Longer-term changes from
baseline in the Imi-Vela population were not statistically signiﬁcant.
Sixteen of 22 patients were old enough to enter puberty during the
extension study (≥7 years of age at baseline). One 13-year-old female
patient had completed pubertal development at baseline. Tanner stage
assessments indicated that patients were at an appropriate stage of
puberty for chronological age.
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4. Discussion
Velaglucerase alfa showed a positive safety proﬁle in children and
adolescents throughout the extension study. The safety results from
this subgroup analysis are consistent with those in the complete
extension study population of 95 adult and pediatric patients [15,16].
No new safety concerns were identiﬁed in the pediatric subgroup.
No SAEs were deemed related to velaglucerase alfa, and no patients
withdrew from the study because of an AE.
One patient died following a SAE of convulsion. The patient was a
6-year-old male from India with a history of anticonvulsant-treated
seizures. He received velaglucerase alfa for 2 years before the terminal
seizure. As reported by his mother, he had involuntary movements
and breathlessness for 2–3 min and then stopped breathing. There
was no associated vomiting, cough or fever. No medical advice was
sought. The investigator did not consider the fatal convulsion to be
related to velaglucerase alfa but instead a result of progression of the
patient's GD. The patient met the eligibility criteria at study entry for
the HGT-GCB-039 non-inferiority trial, as he was diagnosed by his
treating physician as having GD1. During study participation, he developed neurologic symptoms suggestive of GD3 and his GBA genotype,
F213I/F213I, has been described in other cases of GD3 [17]. This patient
retained a diagnosis of GD1 at the time of his death. This is the only
death reported in a velaglucerase alfa clinical trial to date.
In the Overall Vela and Imi-Vela populations, increases in hemoglobin concentration and platelet count, as well as decreases in spleen and
liver volumes were seen, indicating beneﬁcial effects of velaglucerase
alfa in pediatric GD1 patients. In the Switch population, primary efﬁcacy
parameters were stable over time. The efﬁcacy results in the pediatric
population reﬂect those seen in the complete extension study population, where Overall Vela and Imi-Vela patients showed signiﬁcant
improvements in hematological parameters and organ volumes during
the ﬁrst 24 months that were maintained with longer-term treatment
[16]; these efﬁcacy parameters were generally stable in the complete
Switch population [15].
The results obtained here with velaglucerase alfa are also comparable to those seen with imiglucerase; in retrospective analyses of registry
data of pediatric patients treated with imiglucerase and/or alglucerase,
normal or near normal values of key disease parameters could be
achieved within 8 years of therapy, and often sooner [8,9].
Changes from baseline in exploratory efﬁcacy parameters over time
displayed trends toward improvement or maintenance. The GD plasma
biomarkers chitotriosidase and CCL18 decreased considerably in Overall
Vela and Imi-Vela patients within the ﬁrst year of ERT and also
decreased in Switch patients following their transition to velaglucerase
alfa. Chitotriosidase and CCL18 are secreted from the activated pathologic macrophages characteristic of GD [9,18].
Bone involvement is considered the most debilitating aspect of GD,
and can lead to complications such as growth retardation and skeletal

Table 3
Median observed values for height and bone age at baseline, and 24, 39 and 51 months.
Time point

Baseline
24 months
39 months
51 months

Efﬁcacy parameter

Height Z-score
Bone age Z-score
Height Z-score
Bone age Z-score
Height Z-score
Bone age Z-score
Height Z-score
Bone age Z-score

Overall Vela

Imi-Vela

Switch

N=8

N=5

N=9

n

Median (range)

n

Median (range)

n

Median (range)

8
8
8
7
7
7
5
3

−1.5 (−2.7, −0.4)
−2.4 (−6.6, 0.0)
−1.1 (−1.7, −0.3)
−0.9 (−3.7, 2.9)
−0.6 (−1.5, 0.1)
−0.2 (−1.1, 2.7)
−0.2 (−2.0, 0.2)
−0.5 (−2.2, 4.1)

5
4
5
5
3
3
3
3

−3.6 (−4.6, −0.7)
−2.4 (−4.7, −2.2)
−2.1 (−3.5, 0.0)
−2.2 (−4.2, −1.4)
−2.2 (−2.7, −1.9)
−2.3 (−4.3, −1.5)
−2.3 (−3.0, −1.2)
−3 (−3.7, −2.9)

9
9
8
8
4
4
2
1

0.7 (−1.1, 1.3)
−0.1 (−2.5, 0.9)
0.7 (−1.3, 1.4)
0.4 (−1.7, 1.5)
0.4 (−1.8, 0.7)
−0.1 (−0.6, 0.8)
0.5 (0.4, 0.5)
0 (0, 0)

No imputation was applied.
Abnormally advanced bone age was deﬁned by a Z-score N2, whereas abnormally retarded bone age was deﬁned by a Z-score b−2.
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deformity in children [19–21]. In this study, eight of 13 treatment-naïve
patients were below the 5th percentile for height Z-score at baseline. Increases were seen in the Overall Vela and Imi-Vela mean height Zscores, consistent with a positive treatment effect on linear growth.
Switch patients had a greater mean height Z-score at baseline than
treatment-naïve patients, which was stable over time. These results
suggest the beneﬁt of early treatment to enable normal growth.
Increases in bone age Z-scores in the Overall Vela population were observed with long-term velaglucerase alfa treatment, and velaglucerase
alfa maintained bone age Z-scores in Switch patients.
No AEs of bone pain or bone crises were reported for any pediatric
patient prior to starting velaglucerase alfa treatment in the preceding
trials; over the course of the extension study only one AE of bone pain
was reported. Andersson et al. also observed a low frequency of new
bone crises in a study of pediatric GD1 patients receiving ERT [8].
Our study is limited by the small number of patients, especially at
later study time points due to patients transitioning to commercial
velaglucerase alfa. Although age- and sex-matched standards were
used for comparison where possible, there was a wide age range and
imbalance in sex representation that must be considered when
interpreting growth parameters. With a minimum age of 2 years for
inclusion in the trials and subsequent enrolment of 3- and 4-year-old
patients, the inclusion age may have been too low to determine whether patients suffered from GD3, as neurologic signs may only manifest
later. Finally, all pediatric-speciﬁc parameters assessed in the study
were exploratory. While they show trends toward improvement with
velaglucerase alfa treatment, additional conﬁrmatory research is
required to validate the ﬁndings.

5. Conclusions
Velaglucerase alfa ERT was well-tolerated, and no new safety
concerns were identiﬁed for pediatric patients compared with adults.
Velaglucerase alfa had a positive effect on key efﬁcacy parameters in
treatment-naïve pediatric patients and maintained parameters in
patients previously treated with imiglucerase.
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